A 24-week, randomised, double-blind, double-dummy parallel-group, multi-centre, active-controlled study to evaluate efficacy and safety of remogliflozin etabonate in subjects with type-2 diabetes mellitus.
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Remogliflozin etabonate (Primary) ; Dapagliflozin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 08 Jan 2018 Status changed from not yet recruiting to recruiting.
- 13 Dec 2017 New trial record